Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy

Thrombosis Research

Volumn 126, Issue 1, 2010, Pages

  Cambronero, Francisco ^a   Vilchez, Juan Antonio ^a   García Honrubia, Antonio ^b   Ruiz Espejo, Francisco ^a   Moreno, Victoria ^a   Hernández Romero, Diana ^a   Bonacasa, Bárbara ^a   González Conejero, Rocío ^c   de la Morena, Gonzalo ^a   Martínez, Pedro ^a   Climent, Vicente ^b   Valdés, Mariano ^a   Marín, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

endothelial function; hypertrophic cardiomyopathy; von Willebrand factor

Indexed keywords

GADOLINIUM PENTETATE; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; GADOLINIUM;

ADULT; ANAMNESIS; ANGINA PECTORIS; ARTICLE; BLOOD GROUP ABO SYSTEM; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC EQUIVALENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUDDEN DEATH; SYNCOPE; TREADMILL EXERCISE; BLOOD; CARDIOMYOPATHY, HYPERTROPHIC; COMPLICATION; DIAGNOSTIC USE; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART MUSCLE ISCHEMIA; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE TEST; GADOLINIUM; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 77953120013     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.01.010     Document Type: Article

References (34)

1. Kodama K., Shigematsu Y., Hamada M., Hiwada K., Kazatani Y., Matsuzaki K., et al. The effect of coronary vasospasm on the direction of ST-segment deviation in patients with both hypertrophic cardiomyopathy and vasospastic angina. Chest 117 (2000) 1300-1308
2. Dimitrow P.P., Krzanowski M., Nizankowski R., Szczeklik A., and Dubiel J.S. Verapamil improves the response of coronary vasomotion to cold pressor test in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy. Cardiovasc Drugs Ther 13 (1999) 259-264
3. Dimitrow P.P., Krzanowski M., Grodecki J., Malecka B., Lelakowski J., Kawecka-Jaszcz K., et al. Verapamil improves the pacing-induced vasodilatation in symptomatic patients with hypertrophic cardiomyopathy. Int J Cardiol 83 (2002) 239-247
4. Camici P.G., and Crea F. Coronary microvascular dysfunction. N Engl J Med 356 (2007) 830-840
5. Knaapen P., Germans T., Camici P.G., Rimoldi O.E., ten Cate F.J., ten Berg J.M., et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 294 (2008) H986-H993
6. Maron B.J., Wolfson J.K., Epstein S.E., and Roberts W.C. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8 (1986) 545-557
7. Schwartzkopff B., Mundhenke M., and Strauer B.E. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol 31 (1998) 1089-1096
8. Suzuki H., Koba S., Katagiri T., Takeyama Y., and Suwa Y. Ultrastructural changes of blood capillaries in patients with microvascular angina, hypertrophic cardiomyopathy, and dilated cardiomyopathy. Am J Cardiovasc Pathol 5 (1995) 19-26
9. Takemura G., Takatsu Y., and Fujiwara H. Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens. Heart 79 (1998) 78-85
10. Tanaka M., Fujiwara H., Onodera T., Wu D.J., Matsuda M., Hamashima Y., et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 75 (1987) 1130-1139
11. Cambronero F., Marin F., Roldan V., Hernandez-Romero D., Valdes M., and Lip G.Y. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 30 (2009) 139-151
12. Dimitrow P.P., Undas A., Bober M., Tracz W., and Dubiel J.S. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep 59 (2007) 715-720
13. Lip G.Y., and Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 34 (1997) 255-265
14. Lip G.Y., Foster W., and Blann A.D. Plasma von Willebrand factor levels and surrogates of atherosclerosis. J Thromb Haemost 3 (2005) 659-661
15. Varol E., Ozaydin M., Sahin M., Altinbas A., and Kosar F. vWf levels as a circulating marker of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Indian Heart J 57 (2005) 655-657
16. Olsson M.L., and Chester M.A. A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Vox Sang 69 (1995) 242-247
17. Paulinska P., Spiel A., and Jilma B. Role of von Willebrand factor in vascular disease. Hamostaseologie 29 (2009) 32-38
18. Felmeden D.C., and Lip G.Y. Endothelial function and its assessment. Expert Opin Investig Drugs 14 (2005) 1319-1336
19. Sato M., Suzuki A., Nagata K., and Uchiyama S. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis 15 (2006) 1-7
20. Dimitrow P.P., Undas A., Bober M., Tracz W., and Dubiel J.S. Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. Heart 94 (2008) e21
21. Le Tourneau T., Susen S., Caron C., Millaire A., Marechaux S., Polge A.S., et al. Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation 118 (2008) 1550-1557
22. Maron B.J., Olivotto I., Bellone P., Conte M.R., Cecchi F., Flygenring B.P., et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39 (2002) 301-307
23. Yarom R., Lewis B.S., Lijovetzky G., Havivi Y., and Chandler J.A. Platelet studies in patients with hypertrophic cardiomyopathy. Cardiovasc Res 16 (1982) 324-330
24. Riazanov A.S., Gabbasov Z.A., and Iurenev A.P. Platelet aggregation in patients with hypertrophic cardiomyopathy. Ter Arkh 72 (2000) 36-38
25. Heldin C.H., and Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1 (1990) 555-566
26. Ross R., Raines E.W., and Bowen-Pope D.F. The biology of platelet-derived growth factor. Cell 46 (1986) 155-169
27. Pohost G.M., Hung L., and Doyle M. Clinical use of cardiovascular magnetic resonance. Circulation 108 (2003) 647-653
28. Moon J.C. What is late gadolinium enhancement in hypertrophic cardiomyopathy?. Rev Esp Cardiol 60 (2007) 1-4
29. Dumont C.A., Monserrat L., Soler R., Rodriguez E., Fernandez X., Peteiro J., et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 60 (2007) 15-23
30. Paya E., Marin F., Gonzalez J., Gimeno J.R., Feliu E., Romero A., et al. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. J Card Fail 14 (2008) 414-419
31. Vita J.A., Treasure C.B., Yeung A.C., Vekshtein V.I., Fantasia G.M., Fish R.D., et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 85 (1992) 1390-1397
32. Ito H., Hirata Y., Hiroe M., Tsujino M., Adachi S., Takamoto T., et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 69 (1991) 209-215
33. Ito H., Hiroe M., Hirata Y., Fujisaki H., Adachi S., Akimoto H., et al. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89 (1994) 2198-2203
34. Leitner G.C., Schmetterer L., Kapiotis S., and Jilma B. Effects of endothelin-1 and phenylephrine on plasma levels of von Willebrand factor and protein S. Thromb Res 125 (2010) e5-e8